BROOKLINE, Mass.--(BUSINESS WIRE)--The American Society of Transplant Surgeons (ASTS) announced that Qizhi Tang, PhD, of the University of California, San Francisco (UCSF) has been awarded a Faculty Research Grant for Biomarker Discovery and Functional Genomics, sponsored by Transplant Genomics Inc. (TGI). The grant was provided to support translational or clinical research projects designed to test the utility of genomic biomarkers developed by TGI in monitoring and managing transplant recipients.
“Our mission is to save and improve lives with transplantation and advance the art and science of transplant surgery,” commented ASTS Incoming President Charles M. Miller, MD, of Cleveland Clinic. “We are delighted that Dr. Tang’s work will be facilitated by the ASTS grants program, and we are pleased to be partnering with Transplant Genomics to advance research in the field of transplantation.”
“This is a significant opportunity for both our organizations to support translational research with the aim of moving advances in science to the clinic,” said TGI President & CEO Dr. Stan Rose. “It embodies our commitment to working closely with the transplant community as we proceed with commercializing our genomic biomarker tests.”
The grant was formally presented at the American Transplant Congress in Philadelphia during the Grants Award Ceremony on Monday, May 4, 2015. Dr. Tang is an Associate Professor of Surgery at UCSF, Department of Transplant Surgery and also serves as Director of the Transplantation Research Laboratory at UCSF Medical Center. She was selected by the ASTS Grants Review Committee for her research proposal, “Cellular and Molecular Correlates of Acute Rejection in HIV-Positive Kidney Transplant Recipients.” The grant will provide support of up to $100,000 per year ($50,000 in cash and up to $50,000 in-kind support) for two years.
About Transplant Genomics Inc.
Transplant Genomics Inc. (TGI) is a molecular diagnostics company committed to improving organ transplant outcomes, with an initial focus on kidney transplant recipients. Working with the transplant community, TGI is commercializing a suite of tests enabling diagnosis and prediction of transplant recipient immune status. Test results will support clinicians with information to optimize immunosuppressive therapy, enhance patient care and improve graft survival. Test services are offered through TGI’s CLIA lab in Pleasanton, CA. www.transplantgenomics.com